The Role of NG2 Proteoglycan in Glioma
Authors:
Open Access
- 1 February 2016
- journal article
- review article
- Published by Elsevier in Translational Oncology
- Vol. 9 (1) , 57-63
Abstract
No abstract availableKeywords
This publication has 71 references indexed in Scilit:
- Collagen VI Ablation Retards Brain Tumor Progression Due to Deficits in Assembly of the Vascular Basal LaminaThe American Journal of Pathology, 2012
- Functional Characterization of an scFv-Fc Antibody that Immunotherapeutically Targets the Common Cancer Cell Surface Proteoglycan CSPG4Cancer Research, 2011
- CSPG4, a potential therapeutic target, facilitates malignant progression of melanomaPigment Cell & Melanoma Research, 2011
- Asymmetry-Defective Oligodendrocyte Progenitors Are Glioma PrecursorsCancer Cell, 2011
- Targeting the NG2/CSPG4 Proteoglycan Retards Tumour Growth and Angiogenesis in Preclinical Models of GBM and MelanomaPLOS ONE, 2011
- Age-dependent fate and lineage restriction of single NG2 cellsDevelopment, 2011
- CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast CancerJNCI: Journal of the National Cancer Institute, 2010
- Pericyte deficiencies lead to aberrant tumor vascularizaton in the brain of the NG2 null mouseDevelopmental Biology, 2010
- The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signalingOncogene, 2008
- Differential phosphorylation of NG2 proteoglycan by ERK and PKCα helps balance cell proliferation and migrationJournal of Cell Biology, 2007